Przemysl Chemiczny

Przemysl Chemiczny, Vol.91, No.3 Entire volume, number list

ISSN: 0033-2496 (Print)

In this Issue (28 articles)

242 - 243	60 Years of the Pharmaceutical Institute in Warsaw Szyprowski AJ
245 - 251	Interview with Mr Janusz Obukowicz, director of the Pharmaceutical Institute of Warsaw Szyprowski AJ, Obukowicz J
253 - 254	Study on the drug at the Institute of Pharmacy - introduction to a series of articles from the Pharmaceutical Institute Kutner A
255 - 262	Innovation in drug development Szelejewski W, Kutner A
264 - 270	Synthesis of amino acid derivatives of 6H-indolo[2,3-b]quinoline Sidoryk K, Szczepek WJ, Kaczmarek L
272 - 275	Use of NMR technique to study process and the reaction products in synthesis of Exemestane Kubiszewski M, Cybulski M, Kaczmarek L
276 - 281	Application of Suzuki reaction for manufacturing an intermediate in synthesis of the pharmaceutical ingredient lapatinib. Use of palladium catalyst without any phosphine ligands Luniewski W, Krzeczynski P, Klos K, Trzcinska K
283 - 287	Novel strategy of synthesis of paricalcitol Chodynski M, Dzikowska J, Gutowska R, Krajewski K, Kubiszewski M, Krupa M, Pietraszek A, Winiarski J, Kutner A
289 - 294	Ezetimibe, the drug for lowering the cholesterol level. The development of process for the preparation of a product with high stereochemical purity Bankowski K, Sidoryk K, Flip K, Chmielowiec U
296 - 301	Advantages and disadvantages syntheses of loteprednol etabonate Bodziachowska-Panfil M, Groman A, Kubiszewski M, Stopa A, Witkowska AB, Szczepek WJ
303 - 305	Efficient synthesis of nepafenac via modified Gassman reaction Cybulski M, Formela A, Mucha M, Klos K
307 - 312	Exploration of reaction parameter space of brinzolamide synthesis Kaczmarek L, Les A, Mucha L, Badowska-Roslonek K, Rosa A
314 - 318	Application of accelerator mass spectrometry (AMS) in early drug development. Part 1. Background and procedures Lipner G, Grynkiewicz G
320 - 325	Application of accelerator mass spectrometry (AMS) in early drug development. Part 2. Synthesis and certification of C-14-labelled compounds Lipner G, Luniewski W, Maruszak W, Grynkiewicz G
327 - 331	Measurements of paricle size and shape distribution. Essential elements of modern pharmaceutical analysis Maruszak W
333 - 341	Analysis of pharmaceutical hydrates Laszcz M, Witkowska AB, Trzcinska K, Kubiszewski M, Kuziak K
343 - 350	Use of mass spectrometry for identification of impurities in pharmaceutical substances and products Giller T, Stolarczyk EU, Eksanow K, Groman A, Luniewski W
352 - 357	Use of gas chromatography for impurities analysis in pharmaceutical products Stolarczyk EU, Groman A, Eksanow K
358 - 364	Determination of the enantiomeric purity and the in-process control by HPLC in the technology for production of optically active ingredients on an example of tolterodine tartrate Puchalska M, Zagrodzka J, Czerniec-Michalik E, Zezula M, Chmiel J, Luniewski W, Zagrodzki B
365 - 371	High performance electrophoretic separations in pharmaceutical analysis Czerniec-Michalik E, Maruszak W, Puchalska M
372 - 375	Manufacturing of modified release tablets Gluch M, Huszcza G
376 - 380	Semisolid formulations of the drugs. Methods for studying the pharmaceutical availability Pesta-Dynda E, Zielinska A, Zagrodzka J, Dworzynska A
381 - 386	Selectivity control in pharmacokinetic studies Musijowski J, Gilant E, Rudzki PJ
387 - 389	The importance of polymorphism in pharmaceutical research Laszcz M, Trzcinska K, Bodziachowska-Panfil M, Maruszak W
389 - 392	Validation of bioanalytical methods. The new guideline of the European Medicines Agency Rudzki PJ, Szlagowska A, Kaza M
392 - 395	Validation of the manufacturing process of pharmaceutical substances. Help in hindrance? Zagrodzki B
396 - 398	Eye drops. Requirements for product and manufacturing process characteristics Zdeb A, Melissa M
399 - 403	From Beilstein to Reaxys Gryta A, Bajda A